Cellceutix Selects Dr. Reddy’s for Formulation of Brilacidin

Cellceutix Corporation, a clinical-stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. for the formulation of the company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.

Source: Cellceutix 

Leave a Reply

Your email address will not be published. Required fields are marked *